KLRS

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Kalaris Therapeutics, Inc.

NASDAQ | KLRS

4.93

USD

$0.00

(

0.00%

)

At Close (As of Oct 15, 2025)

$45.26M

Market Cap

-

P/E Ratio

-2.71

EPS

$24.15

52 Week High

$2.14

52 Week Low

HEALTHCARE

Sector

KLRS Chart

Recent Chart
Price Action

KLRS Technicals

Tags:

KLRS Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$13M
Selling General And Administrative $1.8M
Research And Development $12M
Operating Expenses $13M
Investment Income Net -
Net Interest Income -$687K
Interest Income -
Interest Expense $687K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$15M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$15M
Comprehensive Income Net Of Tax -
Ebit -$13M
Ebitda -$14M
Net Income -$15M

Revenue & Profitability

Earnings Performance

KLRS Financials

yearly Balance Sheet (As of Dec 31, 2023)

Field Value (USD)
Total Assets $3.3M
Total Current Assets $3.3M
Cash And Cash Equivalents At Carrying Value $3.2M
Cash And Short Term Investments $3.2M
Inventory -
Current Net Receivables -
Total Non Current Assets $0
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $164K
Other Non Current Assets -
Total Liabilities $48M
Total Current Liabilities $3.9M
Current Accounts Payable $2.4M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $44M
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $1.6M
Other Non Current Liabilities -
Total Shareholder Equity -$45M
Treasury Stock -
Retained Earnings -$47M
Common Stock -
Common Stock Shares Outstanding $19M

yearly Cash Flow (As of Dec 31, 2023)

Field Value (USD)
Operating Cashflow -$14M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $14M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$15M

yearly Income Statement (As of Dec 31, 2023)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$13M
Selling General And Administrative $1.8M
Research And Development $12M
Operating Expenses $13M
Investment Income Net -
Net Interest Income -$687K
Interest Income -
Interest Expense $687K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$15M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$15M
Comprehensive Income Net Of Tax -
Ebit -$13M
Ebitda -$14M
Net Income -$15M

KLRS News

KLRS Profile

Kalaris Therapeutics, Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Kalaris Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Palo Alto, California, dedicated to developing innovative therapies for neovascular retinal diseases, thereby addressing critical unmet medical needs in ocular health. The firm harnesses advanced research and development capabilities to create transformative treatments aimed at improving patient outcomes. With a strong pipeline and a team of seasoned professionals, Kalaris is well-positioned to make significant contributions to the ophthalmology sector, navigating the competitive biotech landscape to drive growth and enhance healthcare solutions.

VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.07%
$0.34
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
IVF
+85.67%
$1.40
BITF
-18.39%
$5.28
CGBS
-39.47%
$0.03
COOT
+173.57%
$2.64
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
ADAP
+6.57%
$0.19
BYND
-22.39%
$0.52
YDKG
-54.14%
$0.08
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
LAES
-2.09%
$7.49
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.12%
$11.74
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
INTC
+4.26%
$37.15
WHWK
+24.28%
$2.61
KVUE
-13.34%
$14.09
ACHR
-8.90%
$11.87
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
ONDS
-13.77%
$8.19
DFLI
-32.48%
$1.33
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
CAN
-14.28%
$1.68
AAL
-4.88%
$11.89
MARA
-11.27%
$20.26
GDXD
-10.20%
$0.60
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
GNPX
-43.39%
$0.47
QBTS
-9.62%
$40.47
BTG
+3.96%
$5.89
FEMY
+33.89%
$0.73
QS
-13.41%
$15.45
VSEE
-13.85%
$0.51
RR
-7.95%
$5.67
GPUS
-6.14%
$0.36
LGCB
+19.39%
$1.97
ABAT
-21.00%
$8.94
NAK
-4.34%
$2.64
SNAP
-1.83%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
UUUU
-12.80%
$21.79
KEY
-5.35%
$16.78
HBAN
-5.00%
$15.39
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
JBLU
-3.63%
$4.76
WTO
-88.87%
$0.13
CLSK
-13.92%
$19.97
SMR
-10.87%
$47.62
T
+0.46%
$26.19
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
SOND
+79.34%
$1.65
AUUD
+0.97%
$2.06
SLNH
-2.33%
$4.19
WULF
-9.53%
$13.99
JOBY
-8.66%
$16.07
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
IONQ
-9.33%
$65.65
APLD
-1.69%
$37.11
TOVX
-48.34%
$0.43
NEHC
+9.12%
$3.35
CLF
-0.07%
$13.95
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-4.90%
$51.16
KDLY
+1.29%
$0.79
AMZN
-0.81%
$213.82
VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
+1.07%
$0.34
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
IVF
+85.67%
$1.40
BITF
-18.39%
$5.28
CGBS
-39.47%
$0.03
COOT
+173.57%
$2.64
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
ADAP
+6.57%
$0.19
BYND
-22.39%
$0.52
YDKG
-54.14%
$0.08
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
LAES
-2.09%
$7.49
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.12%
$11.74
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
INTC
+4.26%
$37.15
WHWK
+24.28%
$2.61
KVUE
-13.34%
$14.09
ACHR
-8.90%
$11.87
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
ONDS
-13.77%
$8.19
DFLI
-32.48%
$1.33
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
CAN
-14.28%
$1.68
AAL
-4.88%
$11.89
MARA
-11.27%
$20.26
GDXD
-10.20%
$0.60
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
GNPX
-43.39%
$0.47
QBTS
-9.62%
$40.47
BTG
+3.96%
$5.89
FEMY
+33.89%
$0.73
QS
-13.41%
$15.45
VSEE
-13.85%
$0.51
RR
-7.95%
$5.67
GPUS
-6.14%
$0.36
LGCB
+19.39%
$1.97
ABAT
-21.00%
$8.94
NAK
-4.34%
$2.64
SNAP
-1.83%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
UUUU
-12.80%
$21.79
KEY
-5.35%
$16.78
HBAN
-5.00%
$15.39
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
JBLU
-3.63%
$4.76
WTO
-88.87%
$0.13
CLSK
-13.92%
$19.97
SMR
-10.87%
$47.62
T
+0.46%
$26.19
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
SOND
+79.34%
$1.65
AUUD
+0.97%
$2.06
SLNH
-2.33%
$4.19
WULF
-9.53%
$13.99
JOBY
-8.66%
$16.07
BAC
-4.03%
$50.17
MU
+4.60%
$200.77
IONQ
-9.33%
$65.65
APLD
-1.69%
$37.11
TOVX
-48.34%
$0.43
NEHC
+9.12%
$3.35
CLF
-0.07%
$13.95
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-4.90%
$51.16
KDLY
+1.29%
$0.79
AMZN
-0.81%
$213.82
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.